Bruker Corporation (BRKR) Guidance & Earnings Results

On 2026-08-04 Bruker Corporation raised guidance: "FY26 revenue $3.54-3.57B (prior $3.44B); non-GAAP EPS $2.10-2.15 (prior $1.83); organic growth 1-2%; currency headwind…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BRKRBruker CorporationFollow BRKR — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 8.8B
P/E TTM: —
Dividend yield: 0.3%
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Raised	FY26 revenue $3.54-3.57B (prior $3.44B); non-GAAP EPS $2.10-2.15 (prior $1.83); organic growth 1-2%; currency headwind ~$0.10. · full year
6 May 26	Reaffirmed	FY2026 revenue $3.57-$3.60B (4-5% yoy, 1-2% organic); non-GAAP EPS $2.10-$2.15 (15-17% yoy) · full year
12 Feb 26	Raised	FY26 revenue guidance $3.57-3.60B, non-GAAP EPS $2.10-2.15
12 Jan 26	Raised	FY2026 organic revenue growth flat to low-single digits; non-GAAP operating margin expansion 250-300 bps; non-GAAP EPS double-digit growth. · full year
3 Nov 25	Lowered	FY2025 non-GAAP EPS $1.85-$1.90 vs $2.41 prior year · full year
4 Aug 25	Lowered	FY25 revenue $3.43-3.50B (prior ~$3.5B+); non-GAAP EPS $1.95-2.05 (prior $2.41); organic revenue -2% to -4%; CER revenue ~+0.5% · full year

Bruker Corporation — questions

What guidance did Bruker Corporation give?: On 2026-08-04: "FY26 revenue $3.54-3.57B (prior $3.44B); non-GAAP EPS $2.10-2.15 (prior $1.83); organic growth 1-2%; currency headwind ~$0.10."
When does Bruker Corporation report earnings?: Bruker Corporation's next earnings report is expected on 2026-11-04.

Every figure on this page comes from Bruker Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.